

DAFTAR PUSTAKA

1. Booth C, Allard S. Blood transfusion. *Transfusion Medicine*. 2017; 28(4): 1–7.
2. Astuti WD, Laksono AD. Keamanan darah di Indonesia. 1st ed. Surabaya: Health Advocacy; 2013.1–5.
3. Luban N. Advances in transfusion medicine : 50 years in hematology. *Hematology*. 2008; (2):8–9.
4. Gernsheimer T, Slichter S. Preservation and clinical use of platelets. In Kaushansky K, Lichtman MA, Prchal JT, Levi MM, Press OW, Burns LJ, et al. *Williams haematology*. New York: McGraw-Hill Education; 2016. 2381–91.
5. Nancy YM, Sumanti D. Latar belakang penyakit pada penggunaan transfusi komponen darah pada anak. *Sari Pediatri*. 2011; 13(3): 159–64.
6. Unit Palang Merah Indonesia Kota Padang. Laporan Tahunan. Kota Padang; Unit Palang Merah Indonesia; 2016.7–10.
7. Szczepiorkowski ZM, Dunbar NM. Transfusion guidelines : when to transfuse. *Transfusion Medicine*. 2013;(1): 638–45.
8. Zeller M. Chapter 18 : Platelet transfusion,alloimmunization and management of platelet refractoriness. In Services CB. *Clinical Guide to Transfusion*. Canada: Canadian Blood Services; 2016. 1–14.
9. Sahu S, Hemiata , Verma A. Adverse events related to blood transfusion. *Indian Journal of Anaesthesia*. 2014; 50(5): 543–53.
10. Rachman A. Trombositopenia refrakter. *Jurnal Penyakit Dalam Indonesia*. 2015; 2(4): 199.
11. Oren. Alloimmunization from transfusions. *Medicine*. 2016; (5): 1–7.
12. Kumar H, Gupta P, Mishra D, Sarkar R, Jaiprakash M. Leucodepletion and blood products. *M JAFI*. 2006; 62(2): 174–7.
13. Watering VD, Hermans J, Witvliet M, Versteegh M, Brand A. HLA and RBC immunization after filtered and buffy coat depleted blood transfusion in

- cardiac surgery : a randomized controlled trial. *Transfusion*. 2003; 43: 765–71.
14. Rebulla P. A mini review on platelet refractoriness. *Haematologica*. 2005; 90: 247–53.
15. Pavenski K, Freedman J, Semple J. HLA alloimmunization against platelet transfusions : pathophysiology, significance, prevention and management. *Tissue Antigens*. 2012; 79: 237–45.
16. Seftel M, Grove G, Petraszko T. Universal leukoreduction in Canada decreases platelet alloimmunization and refractoriness. *Blood*. 2004; 103: 333–9.
17. Bianchi M, Vaglio S, Pupella S, Marano G, Facco G, Liumbruno GM, et al. Leucoreduction of blood components : an effective way to increase blood safety ? *Blood Transfus*. 2016; 14: 214–27.
18. Sharma R, Neelam M. Leukoreduced blood components : advantages and strategies for its implementation in developing countries. *Asian J Transfusions Sci*. 2010; 4(1): 3–8.
19. You J, Jiang X, Zhu A. The study of leukocyte filtration in preventing platelet transfusion refractoriness. *J Clin Transfus Lab Med*. 2012; 14(4): 295–7.
20. The Trial to Reduce Alloimmunization to Platelet Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. *N Engl J Med*. 1997; 557: 1861–8.
21. Gombotz H, Dehkharghany A. Clinical consequences of leukocyte reduction. *European Society of Anaesthesiologists*. 2004; (1): 235–40.
22. Djoerban Z. Dasar-dasar transfusi darah. In *Buku Ajar Ilmu Penyakit Dalam Jilid II Edisi IV*. Jakarta: Balai Penerbit FKUI; 2007. 682–4.
23. Wang Q, Yang J, Stevens L, Wang D. Research progress of platelet transfusion in China. *Transfus Med Rev*. 2016; (1): 1–5.
24. Cardigan R, Williamson L. The quality of platelets after storage for 7 days. *Transfus Med*. 2003 March; 13: 173–87.
25. Dumont LJ, Dumont DF, Unger ZM, Siegel A, Szczepiorkowski ZM, Corson

- JS, et al. A randomized controlled trial comparing autologous radiolabeled in vivo platelet recoveries and survivals of 7 days stored platelet rich plasma and buffy coat platelets from the same subjects. *Transfusion*. 2011; 51(6): 1241–8.
26. Kaushansky K, Lichtman MA, Prchal JT, Levi MM, Press OW, Burns LJ, et al. *Williams Hematology*. 9th ed. New York: McGraw-Hill Education; 2016. 541–58.
27. Ness P, Braine H, King K. Single-donor platelets reduce the risk of septic platelet transfusion reactions. *Transfusion*. 2001; 41: 857–81.
28. Heddle N, Cook R, Blajchman M. Assessing the effectiveness of whole blood-derived platelets stored as a pool : a randomized block noninferiority trial. *Transfusion*. 2005; 45: 896–9.
29. Heddle N, Arnold D, Boye D. Comparing the efficacy and safety of apheresis and whole blood derived platelet transfusions : A systematic review. *Transfusion*. 2008; 48: 1447–52.
30. Haroen H. Darah dan komponen : komposisi, indikasi dan cara pemberian. In Sudoyo A, Setiyohadi B, Alwi I, Simadibrata M, Setiati S, editors. *Buku Ajar Ilmu Penyakit Dalam Jilid II Edisi IV*. Jakarta: Pusat Penerbitan Departemen Ilmu Penyakit Dalam FKUI; 2006. 675–80.
31. Kaufman R, Djulbegovic B, Gernsheimer T. Platelet transfusion : a clinical practice guideline from the AABB. *Ann Intern Med*. 2015; 162: 205–8.
32. Zeidler K, Arn K, Senn O. Optimal preprocedural platelet transfusion threshold for central venous catheter insertions in patients with thrombocytopenia. *Transfusion*. 2011; 51: 2269–73.
33. Haas B, Chittams J, Trerotola S. Large-bore tunneled central venous catheter insertion in patients with coagulopathy. *J Vasc Interv Radiol*. 2010; 21: 212.
34. Howard S, Gajjar A, Ribeiro. Safety of lumbar puncture for children with acute lymphoblastic leukemia and thrombocytopenia. *JAMA*. 2000; 284: 2222.
35. Vavricka S, Walter R, Irani S. Safety of lumbal puncture for adults with acute leukemia and restrictive prophylactic platelet transfusion. *Ann Hematol*. 2003;

82: 570.

36. Haas F, VanRhenen D, deVries R. National Users' Board Sanquin Blood Supply : Blood transfusion guideline. 2011.
37. Holcomb J, Tilley B, Baraniuk S. PROPPR Study Group : Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs. a 1:1:2 ratio and mortality in patients with severe trauma: The PROPPR Randomized Clinical Trial. *JAMA*. 2015; 313: 483–91.
38. Hod E, Schwartz J. Platelet transfusion refractoriness. *British Journal of Haematology*. 2008; 142: 348–60.
39. Shastry S, Chaudhary R. Clinical factors influencing corrected count increment. *Transfusion and Apheresis Science*. 2012; 47: 327–30.
40. Holbro A, Infanti L, Sigle J, Buser A. Platelet transfusion : basic aspects. *The European Journal of Medical Sciences : Swiss Medical Weekly*. 2013; 143: 1–10.
41. Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness and platelet transfusion intervals in thrombocytopenic patients. *Transfusion Medicine*. 2003; 105: 4106–14.
42. Kerkhoffs JLH. Efficacy of platelet transfusions. 1st ed. Leiden : Haga Teaching Hospital; 2012. 54–84
43. Blackall D. Alloimmunization from transfusions. *Medscape*. 2017.
44. McFarland JG. Platelet immunology and alloimmunization. In Simon TL, McCullough J, Snyder L, Solheim BG, Strauss G, editors. *Rossi's principle of transfusion medicine*. Milwaukee: John Wiley & Sons, Ltd; 2016. 215–27.
45. Inverardi D, Bocchio C, Rossi L. Clinical, immunologic and technical factors affecting recovery of platelet count after platelet transfusion. *Haematologica*. 2002; 87: 893–4.
46. Friedman D, Lukas M, Jawad A, Larson P, Ohene-frempong K, Manno C. Alloimmunization to platelets in heavily transfused patients with sickle cell disease. *Blood*. 1996; 88(8): 3216–22.

47. Abbas AK, Lichtman AH, Pillai S. Basic immunology : functions and disorders of the immune system. 5th ed. Missouri: Elsevier; 2016. 32–7
48. Sweeney J, Heaton A. Clinical benefits of leukodepleted blood products Germany: Springer-Verlag; 1995. 45–71.
49. Bruil A, Beugeling T, Feijen J, Aken WGV. The mechanisms of leukocyte removal by filtration. *Transfusion Medicine Reviews*. 1995; IX(2): 145–66.
50. Oksanen K. Leukocyte-depleted blood components prevent platelet refractoriness in patients with acute myeloid leukemia. *European Journal of Haematology*. 1994; 53(2): 100–7.
51. Blumberg N, Heal JM. Optimizing platelet transfusion therapy. *Blood reviews*. 2004; 18(3): 149–65.
52. Myllyla G, Saarinen U, Koskimies S. Systematic use of leukocytes-free blood components to prevent alloimmunization and platelet refractoriness in multitransfused patients with cancer. *Vox Sanguinis*. 1993; 65: 286–92.
53. Hao B, Wang Y, Zhou J, Shao S, Dong X. Comparison between the clinical efficacy of platelet concentrates, derived from buffy coat and apheresis in tumor patients. *Oncology Letters*. 2017; 14: 1445–8.
54. Lubis M, Sudoyo AW, Effendy S, Djumhana T, Kuntjoro. Hubungan antibodi anti trombosit terhadap respon transfusi trombosit pada pasien hemato-onkologi yang mendapatkan multitransfusi trombosit di RS Dr. Cipto Mangunkusumo. *Jurnal Penyakit Dalam Indonesia*. 2015; 2(4): 200–8.
55. Jaime-perez JC, Vazquez-Hernandez KE, Jimenez-Castillo A, Fernandez LT, Salazar-Riojas R, Gomez-Almaguer D. Platelet survival in hematology patients assessed by the corrected count increment and other formulas. *Am J Clin Pathol*. 2018; 150: 267–72.
56. Triulzi DJ, Assmann SF, Strauss RG, Hess JR, Kaufman RM, Granger S, et al. The impact of platelet transfusion characteristics on post transfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia. *Blood*. 2012; 119(23): 5553–62.
57. Novotny VMJ. Prevention and management of platelet transfusion

- refractoriness. *Vox Sang.* 1999; 76(1): 1–13.
58. Kluter H, Dorges L, Maass E, Wagner T, Bartels H, Kirchner H. In-vivo evaluation of random donor platelet concentrates from pooled buffy coats. *Ann Hematol.* 1996; 73: 85–9.
59. Anderson N, Gray S, Coplestone J, Chan D, Hamon M, Prentice A, et al. A prospective randomized study of three types of platelet concentrates in patients with haematological malignancy : corrected count increments and frequency of onhemolytic febrile transfusion reactions. *Transfus Med.* 1997; 7: 33–9.
60. Jackman RP, Deng X, Bolgiano D, Utter GH, Schechterly C. Leukoreduction and ultraviolet treatment reduce both the magnitude and the duration of the HLA antibody response. *Transfusion.* 2014; 54(3): 672–80.
61. Williamson LM, Wimperis JZ, Williamson P, Coplestone A, Gooi HC, Morgenstern GR, et al. Bedside filtration of blood products in the prevention of HLA alloimmunization. *Blood.* 1994; 83(10): 3028–35.
62. Fletcher CH, DomBourian MG, Millward PA. Platelet transfusion for patients with cancer. *Cancer Control.* 2015; 22(1): 47–51.

